FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Fortress Biotech, Inc. Stock AnalysisComprehensive stock analysis for Fortress Biotech, Inc. (FBIO) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisFBIO
FBIO
Fortress Biotech, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
FBIO
Home🔹Stocks🔹Fortress Biotech, Inc.

Fortress Biotech, Inc.

🇺🇸FBIO•NASDAQ

Fortress Biotech, Inc.

🇺🇸FBIO•NASDAQ
Market cap
$83.71M
Sentiment

Your view on FBIO

Mkt Cap
$83.71M
Sentiment
Your view
FBIO
Fortress Biotech, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
FBIO
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Fortress Biotech, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Lindsay Allan Rosenwald
Headquarters
US
Industry
Biotechnology
Sector
Healthcare
CEO
Lindsay Allan Rosenwald
Headquarters
US
Description

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products.

The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne.

It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children.

The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101.

Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies.

The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Fortress Biotech, Inc., and the rating behind it. FBIO last traded at $2.52, 0.8× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Fortress Biotech, Inc.. Starting points for Fortress Biotech, Inc.: P/E 0.8, EPS $3.53, beta 1.19 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Fortress Biotech, Inc.. Fortress Biotech, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Fortress Biotech, Inc.. Trailing twelve-month EPS for Fortress Biotech, Inc. stands at $3.53. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Fortress Biotech, Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Fortress Biotech, Inc. valued side by side against its closest peers. Fortress Biotech, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Fortress Biotech, Inc., and how their positions are changing. At a $83.7M market value, institutional positions materially move Fortress Biotech, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Fortress Biotech, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Fortress Biotech, Inc.. Fortress Biotech, Inc. is a $83.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Fortress Biotech, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Fortress Biotech, Inc.. Coverage tracks Fortress Biotech, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • ADAG — Adagene Inc.
  • CRVO — CervoMed Inc.
  • GANX — Gain Therapeutics, Inc.
  • IMUX — Immunic, Inc.
  • NTRB — Nutriband Inc.
  • PMVP — PMV Pharmaceuticals, Inc.
  • RLMD — Relmada Therapeutics, Inc.
  • TCRX — TScan Therapeutics, Inc.

More Biotechnology companies

  • VINC — Vincerx Pharma, Inc.
  • VIR — Vir Biotechnology, Inc.
  • VIVS — VivoSim Labs, Inc.
  • VKTX — Viking Therapeutics, Inc.
  • VNDA — Vanda Pharmaceuticals Inc.
  • VOR — Vor Biopharma Inc.
  • VPRO — Viropro Inc.
  • VRAX — Virax Biolabs Group Limited
  • VRCA — Verrica Pharmaceuticals Inc.
  • VRCI — Verde Science, Inc.
  • VRDN — Viridian Therapeutics, Inc.
  • VRPX — Virpax Pharmaceuticals, Inc.

ETFs holding Fortress Biotech, Inc.

  • IWC — iShares Micro-Cap ETF (0.02%)
  • VXF — Vanguard Extended Market ETF (0.00%)
  • VUS.TO — Vanguard U.S. Total Market Index ETF (CAD-hedged) (0.00%)
  • VUN.TO — Vanguard U.S. Total Market Index ETF (0.00%)
  • VTS.AX — Vanguard U.S. Total Market Shares Index ETF (0.00%)
  • VTI — Vanguard Total Stock Market ETF (0.00%)

News

Latest Market News